Roka Bioscience Inc. (NASDAQ:ROKA) Given Consensus Rating of “Sell” by Brokerages
Shares of Roka Bioscience Inc. (NASDAQ:ROKA) have earned a consensus broker rating score of 4.00 (Sell) from the one brokers that cover the stock, Zacks Investment Research reports.
Zacks has also given Roka Bioscience an industry rank of 103 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research upgraded shares of Roka Bioscience from a “sell” rating to a “hold” rating in a research report on Wednesday, July 6th.
Shares of Roka Bioscience (NASDAQ:ROKA) opened at 0.721 on Thursday. The stock’s market capitalization is $12.89 million. The company’s 50-day moving average is $0.94 and its 200-day moving average is $0.75. Roka Bioscience has a 12 month low of $0.50 and a 12 month high of $2.46.
Roka Bioscience (NASDAQ:ROKA) last issued its earnings results on Friday, August 5th. The company reported ($0.43) earnings per share for the quarter. The business had revenue of $1.82 million for the quarter, compared to the consensus estimate of $1.78 million. Roka Bioscience had a negative return on equity of 82.40% and a negative net margin of 530.04%. Equities research analysts expect that Roka Bioscience will post ($2.00) earnings per share for the current fiscal year.
Roka Bioscience Company Profile
Roka Bioscience, Inc is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Roka Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roka Bioscience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.